261 related articles for article (PubMed ID: 32087614)
1. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
Katayama M; Ohata K; Miyazaki T; Katayama R; Wakamatsu N; Ohno M; Yamashita T; Oikawa T; Sugaya T; Miyazaki M
J Vet Intern Med; 2020 Mar; 34(2):761-769. PubMed ID: 32087614
[TBL] [Abstract][Full Text] [Related]
2. Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study.
Katayama M; Miyazaki T; Ohata K; Oikawa T; Kamiie J; Sugaya T; Miyazaki M
J Vet Med Sci; 2019 Dec; 81(12):1868-1872. PubMed ID: 31645505
[TBL] [Abstract][Full Text] [Related]
3. Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease.
Watanabe A; Ohata K; Oikawa T; Sugaya T; Miyazaki M; Satoh H; Katayama M
Can J Vet Res; 2021 Apr; 85(2):156-160. PubMed ID: 33883825
[TBL] [Abstract][Full Text] [Related]
4. Urinary liver-type fatty acid-binding protein in clinically healthy elderly cats: Evaluation of its potential to detect IRIS stage 1 chronic kidney disease and borderline proteinuria.
Kongtasai T; Paepe D; Mortier F; Marynissen S; Meyer E; Duchateau L; Daminet S
Vet Med Sci; 2023 Jan; 9(1):3-12. PubMed ID: 36418182
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs.
Takashima S; Nagamori Y; Ohata K; Oikawa T; Sugaya T; Kobatake Y; Nishii N
J Vet Med Sci; 2021 Sep; 83(9):1465-1471. PubMed ID: 34526412
[TBL] [Abstract][Full Text] [Related]
6. Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism.
Kongtasai T; Meyer E; Paepe D; Marynissen S; Smets P; Mortier F; Demeyere K; Vandermeulen E; Stock E; Buresova E; Defauw P; Duchateau L; Daminet S
J Vet Intern Med; 2021 May; 35(3):1376-1388. PubMed ID: 33723886
[TBL] [Abstract][Full Text] [Related]
7. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.
Fujita D; Takahashi M; Doi K; Abe M; Tazaki J; Kiyosue A; Myojo M; Ando J; Fujita H; Noiri E; Sugaya T; Hirata Y; Komuro I
Heart Vessels; 2015 May; 30(3):296-303. PubMed ID: 24554034
[TBL] [Abstract][Full Text] [Related]
8. Urinary liver-type fatty acid-binding protein in pediatric nephrotic syndrome and tubular dysfunction.
Nishida M; Kawakatsu H; Hamaoka K
Pediatr Int; 2018 May; 60(5):442-445. PubMed ID: 29460503
[TBL] [Abstract][Full Text] [Related]
9. [L-type fatty acid binding protein (L-FABP) and kidney disease].
Kamijo-Ikemori A; Sugaya T; Kimura K
Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
[TBL] [Abstract][Full Text] [Related]
11. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
12. Urinary NGAL, KIM-1 and L-FABP concentrations in antenatal hydronephrosis.
Noyan A; Parmaksiz G; Dursun H; Ezer SS; Anarat R; Cengiz N
J Pediatr Urol; 2015 Oct; 11(5):249.e1-6. PubMed ID: 26096437
[TBL] [Abstract][Full Text] [Related]
13. Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Worsening Renal Function in Patients With Acute Heart Failure.
Okubo Y; Sairaku A; Morishima N; Ogi H; Matsumoto T; Kinoshita H; Kihara Y
J Card Fail; 2018 Aug; 24(8):520-524. PubMed ID: 30026130
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
Mou S; Wang Q; Li J; Shi B; Ni Z
Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699
[TBL] [Abstract][Full Text] [Related]
15. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
17. Urinary Liver-Type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Patients on Peritoneal Dialysis.
Torigoe K; Muta K; Tsuji K; Yamashita A; Ota Y; Kitamura M; Mukae H; Nishino T
Med Sci Monit; 2020 Dec; 26():e928236. PubMed ID: 33347426
[TBL] [Abstract][Full Text] [Related]
18. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
[TBL] [Abstract][Full Text] [Related]
19. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K
Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260
[TBL] [Abstract][Full Text] [Related]
20. [Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease].
Kamijo A; Sugaya T; Hikawa A; Kimura K
Rinsho Byori; 2003 Mar; 51(3):219-24. PubMed ID: 12707994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
